Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
23 hedge funds and large institutions have $2.54M invested in Vyant Bio, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
15% less funds holding
Funds holding: 27 → 23 (-4)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
19% less capital invested
Capital invested by funds: $3.12M → $2.54M (-$583K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.9K |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
+$27.9K |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.36K |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$3.14K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BF
Blankinship & Foster
Solana Beach,
California
|
-$277K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$109K |
| 3 |
Renaissance Technologies
New York
|
-$89.4K |
| 4 |
VF
Virtu Financial
New York
|
-$64K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$55K |
VYNT Hedge Fund Activity: Q1 2022 in Review
23 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q1 2022, worth a combined $2.54M — down 19% from $3.12M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VYNT and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $40.9K. The largest seller was Blankinship & Foster, exiting entirely with an estimated $277K sold.
- 23 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q1 2022, down from 27 in Q4 2021.
- Funds reported $2.54M of Vyant Bio, Inc. Common Stock stock for Q1 2022, down 19% quarter-over-quarter.
- 4 funds opened new Vyant Bio, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q1 2022 was Citadel Advisors, an estimated $40.9K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q1 2022 was Blankinship & Foster, an estimated $277K sold.
Based on aggregated 13F filings for Q1 2022.